📣 VC round data is live. Check it out!

NeuroPace Valuation Multiples

Discover revenue and EBITDA valuation multiples for NeuroPace and similar public comparables like Sofwave Medical, Japan Lifeline, Tactile Medical, Bioventus and more.

NeuroPace Overview

About NeuroPace

NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.


Founded

1997

HQ

United States

Employees

184

Financials (LTM)

Revenue: $100M
EBITDA: ($7M)

EV

$573M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

NeuroPace Financials

NeuroPace reported last 12-month revenue of $100M and negative EBITDA of ($7M).

In the same LTM period, NeuroPace generated $81M in gross profit, ($7M) in EBITDA losses, and had net loss of ($20M).

Revenue (LTM)


NeuroPace P&L

In the most recent fiscal year, NeuroPace reported revenue of $100M and EBITDA of ($5M).

NeuroPace is unprofitable as of last fiscal year, with gross margin of 77%, EBITDA margin of (5%), and net margin of (21%).

See analyst estimates for NeuroPace
LTMLast FY202320242025202620272028
Revenue$100M$100M$65M$80M$100M
Gross Profit$81M$77M$48M$59M$77M
Gross Margin81%77%74%74%77%
EBITDA($7M)($5M)($23M)($17M)($12M)
EBITDA Margin(7%)(5%)(35%)(21%)(12%)
EBIT Margin(16%)(16%)(42%)(27%)(16%)
Net Profit($20M)($21M)($33M)($27M)($21M)
Net Margin(20%)(21%)(50%)(34%)(21%)
Net Debt-$37M---

Financial data powered by Morningstar, Inc.

NeuroPace Stock Performance

NeuroPace has current market cap of $556M, and enterprise value of $573M.

Market Cap Evolution


NeuroPace's stock price is $16.32.

NeuroPace share price decreased by 1.2% in the last 30 days, and increased by 47.6% in the last year.

NeuroPace has an EPS (earnings per share) of $-0.63.

See more trading valuation data for NeuroPace
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$573M$556M-1.2%-1.2%24.1%47.6%$-0.63

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

NeuroPace Valuation Multiples

NeuroPace trades at 5.7x EV/Revenue multiple, and (86.6x) EV/EBITDA.

See NTM and 2027E valuation multiples for NeuroPace

EV / Revenue (LTM)


NeuroPace Financial Valuation Multiples

As of June 3, 2026, NeuroPace has market cap of $556M and EV of $573M.

NeuroPace has a P/E ratio of (27.2x).

LTMLast FY202320242025202620272028
EV/Revenue5.7x5.7x8.8x7.2x5.7x
EV/EBITDA(86.6x)(114.3x)(25.1x)(34.6x)(47.5x)
EV/EBIT(35.8x)(35.1x)(21.1x)(26.4x)(35.1x)
EV/Gross Profit7.1x7.4x11.9x9.7x7.4x
P/E(27.2x)(25.9x)(16.9x)(20.5x)(25.9x)
EV/FCF(65.6x)(50.5x)(28.8x)(31.4x)(50.5x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified NeuroPace Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

NeuroPace Margins & Growth Rates

NeuroPace decreased revenue by 0% but EBITDA grew by 76% in the last fiscal year.

In the most recent fiscal year, NeuroPace reported gross margin of 77%, EBITDA margin of (5%), and net margin of (21%).

See estimated margins and future growth rates for NeuroPace

NeuroPace Margins

Last FY202420252026202720282029
Gross Margin77%74%77%82%
EBITDA Margin(5%)(21%)(12%)(9%)
EBIT Margin(16%)(27%)(16%)(15%)
Net Margin(21%)(34%)(21%)(19%)
FCF Margin(11%)(23%)(11%)(4%)

NeuroPace Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth(0%)22%25%(0%)
Gross Profit Growth6%23%31%6%
EBITDA Growth76%(27%)(27%)(27%)
EBIT Growth(5%)(20%)(25%)(5%)
Net Profit Growth(11%)(18%)(21%)(11%)
FCF Growth(64%)(8%)(38%)(64%)

Data powered by FactSet, Inc. and Morningstar, Inc.

NeuroPace Operational KPIs

NeuroPace's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.5M for the same period.

NeuroPace's Rule of 40 is (9%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

NeuroPace's Rule of X is (9%) (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for NeuroPace
LTMLast FY202320242025202620272028
Rule of 403%(9%)---
Bessemer Rule of X18%(9%)---
Revenue per Employee-$0.5M---
Opex per Employee-$0.5M---
S&M Expenses to Revenue48%47%--47%
G&A Expenses to Revenue20%19%--19%
R&D Expenses to Revenue28%28%32%30%28%
Opex to Revenue-94%115%101%94%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

NeuroPace Competitors

NeuroPace competitors include Sofwave Medical, Japan Lifeline, Tactile Medical, Bioventus, Polynovo, Beta Bionics, Cytek Biosciences, Cerus, IBA Group and MiMedx Group.

Most NeuroPace public comparables operate across Medical Devices, DeepTech and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Sofwave Medical6.0x-68.7x-
Japan Lifeline1.4x1.3x5.8x5.6x
Tactile Medical1.4x1.4x10.6x10.1x
Bioventus1.4x1.3x6.8x6.7x
Polynovo5.9x5.0x72.0x57.2x
Beta Bionics3.8x3.3x(7.1x)(5.9x)
Cytek Biosciences1.5x1.5x(463.4x)(186.0x)
Cerus2.4x2.3x58.8x40.6x

This data is available for Pro users. Sign up to see all NeuroPace competitors and their valuation data.

Start Free Trial

NeuroPace VC Funding History

Before going public, NeuroPace raised $159M in total equity funding, across 4 rounds.


NeuroPace Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Aug-20Undisclosed stage-$34M-NeuroPace is a commercial-stage medical device company based in Mountain View, California, focused on treating drug-resistant epilepsy with its RNS System, a brain-responsive neurostimulator that delivers personalized, real-time treatment at the seizure source to reduce or eliminate seizures. On August 31, 2020, the company raised $67 million in an equity financing round led by Accelmed Partners, with participation from investors including KCK Group and OrbiMed Advisors, to accelerate commercial growth of the RNS System and advance new FDA-cleared indications. This round is part of NeuroPace's broader funding history, having raised a total of $278.05 million across 19 rounds from 17 investors as of the latest data. Post-round, NeuroPace went public, with a valuation of $445 million noted in April 2021, and continued raising capital, including a PIPE in November 2022. The RNS System is positioned as a differentiated therapy for epilepsy patients unresponsive to drugs, with potential expansion into other brain disorders, supported by proprietary device data and customizable treatment.
Aug-20Undisclosed stageAccelmed; KCK; OrbiMed; Revelation Partners; Soleus Capital$33M-NeuroPace, Inc. is a Silicon Valley-based medical technology company developing the RNS System, an innovative responsive neurostimulation device for treating refractory focal epilepsy by continuously monitoring EEG data and delivering closed-loop stimulation. The company announced a $67 million financing round on August 31, 2020, led by Accelmed Partners with participation from Revelation Partners, Soleus Capital, KCK Group, OrbiMed Advisors, and an unnamed strategic investor. This included $33 million in new equity and $34 million from convertible debt, with an additional $27 million committed in a second tranche to support commercial expansion and pursuit of expanded indications. The funding aims to accelerate growth in the large unmet market for epilepsy neuromodulation, where NeuroPace's technology sets the standard with unmatched clinical outcomes. Accelmed Partners, a New York-based private equity firm focused on commercial-stage HealthTech, highlighted the company's differentiated technology and market potential. NeuroPace has raised a total of $278.05 million across 19 funding rounds from 17 investors, with this 2020 round matching the specified investors and lead. For FY 2020, near the round date, NeuroPace reported revenue of $41.14 million, though a later April 2021 valuation was $445 million and the company went public thereafter. NeuroPace continues to target neurological disorders beyond epilepsy.
Oct-17Undisclosed stageKCK; OrbiMed$74M-NeuroPace, a Mountain View, California-based medical technology company founded in 1997, develops the RNS System, an implantable neurostimulation device that monitors brain activity and delivers responsive stimulation to reduce seizures in patients with drug-resistant partial onset epilepsy. The device has FDA approval and had been implanted in 1,300 patients prior to the funding. Approximately 3.4 million Americans suffer from epilepsy, with many cases unresponsive to medication. On October 24, 2017, NeuroPace closed a $74 million equity funding round co-led by KCK Group and OrbiMed Advisors to accelerate commercialization of the RNS System, including expanding its marketing organization and educational programs for patients and physicians like neurologists and neurosurgeons. Prior to this, the company had raised about $180 million in total funding, with its most recent prior round being $18 million in 2013. Investors also include Johnson & Johnson Innovation (JJDC), Kleiner Perkins Caufield and Byers, Interwest Partners, Domain Associates, MedVenture Associates, New Enterprise Associates, DAG Ventures, and Glynn Capital Management. The funding supports bringing the brain-responsive neurostimulation technology to more patients, with potential expansion to other neurological conditions. NeuroPace's CEO at the time, Frank Fischer, highlighted the device's remote monitoring capabilities for physicians to guide treatment. KCK Group's Greg Garfield praised the brain-computer interface technology's innovation.
Jul-13Undisclosed stageInterWest Partners; Johnson & Johnson Development Corporation; Kleiner Perkins; MedVenture Associates; New Enterprise Associates$18M-NeuroPace is a US-based medical device company founded in 1997, specializing in an implantable neurostimulation system called the RNS System designed to reduce the frequency of partial onset seizures in epilepsy patients difficult to control with drugs. The device received FDA Pre-Market Approval in late 2013, with commercial rollout beginning in early 2014, and by 2017 had been implanted in 1,300 patients. The company targets the epilepsy market, where approximately 3.4 million Americans suffer from the condition according to CDC data. This round aligns with the specified investors including lead Johnson & Johnson Development Corporation (JJDC), InterWest Partners, Kleiner Perkins, MedVenture Associates, and New Enterprise Associates, along with others like Domain Associates, DAG Ventures, and Glynn Capital Management. Prior to this, NeuroPace had accumulated about $180 million in total funding. Brad Vale from JJDC served on the board as of 2011. The 2013 funding supported development and eventual commercialization of the RNS System post-FDA approval. A later 2017 round raised $74 million co-led by Orbimed and KCK Group to accelerate commercialization.

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About NeuroPace

When was NeuroPace founded?NeuroPace was founded in 1997.
Where is NeuroPace headquartered?NeuroPace is headquartered in United States.
How many employees does NeuroPace have?As of today, NeuroPace has over 184 employees.
Who is the CEO of NeuroPace?NeuroPace's CEO is Joel Becker.
Is NeuroPace publicly listed?Yes, NeuroPace is a public company listed on Nasdaq.
What is the stock symbol of NeuroPace?NeuroPace trades under NPCE ticker.
When did NeuroPace go public?NeuroPace went public in 2021.
Who are competitors of NeuroPace?NeuroPace main competitors include Sofwave Medical, Japan Lifeline, Tactile Medical, Bioventus, Polynovo, Beta Bionics, Cytek Biosciences, Cerus, IBA Group, MiMedx Group.
What is the current market cap of NeuroPace?NeuroPace's current market cap is $556M.
What is the current revenue of NeuroPace?NeuroPace's last 12 months revenue is $100M.
What is the current revenue growth of NeuroPace?NeuroPace revenue growth (NTM/LTM) is 10%.
What is the current EV/Revenue multiple of NeuroPace?Current revenue multiple of NeuroPace is 5.7x.
Is NeuroPace profitable?No, NeuroPace is not profitable.
What is the current EBITDA of NeuroPace?NeuroPace has negative EBITDA and is not profitable.
What is NeuroPace's EBITDA margin?NeuroPace's last 12 months EBITDA margin is (7%).
What is the current EV/EBITDA multiple of NeuroPace?Current EBITDA multiple of NeuroPace is (86.6x).
What is the current FCF of NeuroPace?NeuroPace's last 12 months FCF is ($9M).
What is NeuroPace's FCF margin?NeuroPace's last 12 months FCF margin is (9%).
What is the current EV/FCF multiple of NeuroPace?Current FCF multiple of NeuroPace is (65.6x).
How many companies NeuroPace has acquired to date?NeuroPace hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies NeuroPace has invested to date?NeuroPace hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to NeuroPace

Lists including NeuroPace

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial